<DOC>
	<DOCNO>NCT00692107</DOCNO>
	<brief_summary>3-D conformal radiotherapy offer opportunity reach high tumor dos acceptable complication rate compare conventional radiotherapy . There retrospective preliminary prospective report well local control / disease free survival ( include PSA control ) use high tumor dos . A prospective randomised phase III study require validate report . The purpose randomized phase III study investigate compare tumor control toxicity prostate cancer patient treat 68 Gy 78 Gy ;</brief_summary>
	<brief_title>Radiotherapy Prostate Cancer : Conventional Dose Versus High Dose</brief_title>
	<detailed_description>Patients stratify hospital , treatment group , age ( neo ) adjuvant hormonal therapy . Four treatment group specific radiation volume define depend estimate risk tumour involvement seminal vesicle ( base T-stage , initial PSA Gleason Score Differentiation Grade ) .The dose deliver daily fraction 2 Gy , five time week . The total duration treatment 7 week patient treat 68 Gy 8 week 78 Gy . Objectives : - To test phase III randomise study hypothesis high radiation dos lead high freedom failure rate localize prostate cancer . - To test hypothesis high freedom failure rate lead long disease-free survival overall survival . - To limit acute late toxicity respect gastro-intestinal urological toxicity . - To evaluate different PSA relate endpoint local failure distant metastasis . - To establish database patient treat escalated dos Dose Volume Histograms normal tissue risk individual patient common toxicity endpoint . - To validate model estimate normal tissue complication probability ( NTCPs ) rectum bladder , base above-mentioned database , obtain reliable parameter value NTCP estimation .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>locally confine adenocarcinoma prostate Tstages PSA &lt; 60ng/ml , except T1a tumor welldifferentiated ( Gleason score &lt; 5 ) T1bc tumor PSAlevels â‰¤ 4 ng/ml Karnofsky Performance Status 80 distant metastasis positive regional lymph node proven surgical cytological sampling anticoagulant previous prostatectomy previous pelvic irradiation</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Dose</keyword>
</DOC>